Webcast, Event, or Conference

»Webcast, Event, or Conference
20 03, 2019

Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019

2019-03-20T13:29:54+00:00

Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019 PALO ALTO, Calif., March 20, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the [...]

Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 20192019-03-20T13:29:54+00:00
13 03, 2019

Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress™ 2019

2019-03-13T14:34:05+00:00

Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress™ 2019 36% Durable Virologic Response at 24 Weeks Post-Treatment PALO ALTO, Calif., March 13, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced a late-breaker [...]

Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress™ 20192019-03-13T14:34:05+00:00
11 03, 2019

Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit

2019-03-11T15:07:06+00:00

Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit PALO ALTO, Calif., March 11, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the Jefferies [...]

Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit2019-03-11T15:07:06+00:00
4 02, 2019

Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans

2019-02-04T15:27:59+00:00

Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans PALO ALTO, Calif., February 4, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced an oral presentation has [...]

Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans2019-02-04T15:27:59+00:00
4 12, 2018

Eiger BioPharmaceuticals to Host R&D Day in New York City

2018-12-04T14:51:54+00:00

Eiger BioPharmaceuticals to Host R&D Day in New York City PALO ALTO, Calif., December 4, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced it will host an R&D Day on December 11, 2018 from 12:00 PM to 2:30 PM EST at [...]

Eiger BioPharmaceuticals to Host R&D Day in New York City2018-12-04T14:51:54+00:00
19 11, 2018

Eiger to Participate in Piper Jaffray Healthcare Conference

2018-11-21T11:28:38+00:00

Eiger to Participate in Piper Jaffray Healthcare Conference PALO ALTO, Calif., November 19, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the 30th Annual Piper Jaffray Healthcare Conference on November 27 [...]

Eiger to Participate in Piper Jaffray Healthcare Conference2018-11-21T11:28:38+00:00
18 10, 2018

Eiger BioPharmaceuticals to Participate at BTIG Biotech Conference

2018-10-18T17:03:58+00:00

Eiger BioPharmaceuticals to Participate at BTIG Biotech Conference PALO ALTO, Calif., October 18, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced the Eiger management team will participate and host 1:1 investor meetings at the BTIG Biotech Conference at the Langham Hotel in New [...]

Eiger BioPharmaceuticals to Participate at BTIG Biotech Conference2018-10-18T17:03:58+00:00
25 09, 2018

Eiger BioPharmaceuticals to Participate in Investor Conferences

2018-09-25T13:50:24+00:00

Eiger BioPharmaceuticals to Participate in Investor Conferences PALO ALTO, Calif., September 25, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that David Cory, President and CEO, will present at two investor conferences in October in New York City. Cantor Fitzgerald 4th [...]

Eiger BioPharmaceuticals to Participate in Investor Conferences2018-09-25T13:50:24+00:00
27 08, 2018

Eiger BioPharmaceuticals to Participate in Investor Conferences

2018-08-29T18:26:56+00:00

Eiger BioPharmaceuticals to Participate in Investor Conferences PALO ALTO, Calif., August 27, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that members of the Eiger management team will participate in multiple investor conferences in September in New York City. Details of [...]

Eiger BioPharmaceuticals to Participate in Investor Conferences2018-08-29T18:26:56+00:00
4 06, 2018

Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™

2018-06-04T15:46:20+00:00

Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™ PALO ALTO, Calif., June 4, 2018 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that an oral presentation [...]

Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™2018-06-04T15:46:20+00:00